Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AZN: AstraZeneca PLC -- Ignore unavailable to you. Want to Upgrade?

To: EdR who wrote (22)	8/30/2002 1:47:00 PM
From: keokalani'nui	Respond to of 35

Press Release Source: IVAX Corporation IVAX Receives Tentative Approval For Tamoxifen Friday August 30, 1:07 pm ET MIAMI--(BUSINESS WIRE)--Aug. 30, 2002--IVAX Corporation (AMEX:IVX - News; LSE:IVX.L) announced today it has received tentative approval from the FDA of its Abbreviated New Drug Application (ANDA) for tamoxifen citrate tablets in 10 mg and 20 mg strengths. Upon final approval, this product will be sold through the company's wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Tamoxifen citrate is used for the treatment of breast cancer. It is the generic equivalent of Nolvadex® Tablets marketed by AstraZeneca. IVAX now currently has 34 ANDAs approvals and two tentative approvals pending at the FDA. The company is continuing its aggressive filing schedule for new ANDA submissions.

To: EdR who wrote (22)	9/17/2002 10:19:46 AM
From: EdR	Read Replies (1) \| Respond to of 35

The FDA is holding a public meeting on IRESSA... <<snip>> ONCOLOGIC DRUGS ADVISORY COMMITTEE DATE: Sept. 24, 0830/1230 LOCATION: Holiday Inn, 8777 Georgia Ave., Silver Spring, MD CONTACT: Karen Templeton-Somers, 301-827-7001 The committee will discuss a new drug application for AstraZeneca Plc's <AZN.L> Iressa for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy.